[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200970398A1 - Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр - Google Patents

Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр

Info

Publication number
EA200970398A1
EA200970398A1 EA200970398A EA200970398A EA200970398A1 EA 200970398 A1 EA200970398 A1 EA 200970398A1 EA 200970398 A EA200970398 A EA 200970398A EA 200970398 A EA200970398 A EA 200970398A EA 200970398 A1 EA200970398 A1 EA 200970398A1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperidine
derivatives
napthaline
mtr
piperazin
Prior art date
Application number
EA200970398A
Other languages
English (en)
Other versions
EA016311B1 (ru
Inventor
Ливен Мерпул
Йоаннес Теодорус Мария Линдерс
Либуше Яроскова
Марсель Вьейевуа
Лео Якобус Йозеф Бакс
Дидье Жан-Код Бертело
Гююске Фредерике Бюсхер
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA200970398A1 publication Critical patent/EA200970398A1/ru
Publication of EA016311B1 publication Critical patent/EA016311B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым производным пиперидин или пиперазин замещенной тетрагидро-нафталин-1-карбоновой кислоты, обладающим ингибирующей активностью в отношении секреции апоВ/МТР и сопутствующей гиполипидемической активностью. Кроме того, изобретение относится к способам получения таких соединений, фармацевтическим композициям, содержащим указанные соединения, а также использованию указанных соединений в качестве лекарственного средства для лечения атеросклероза, панкреатита, ожирения, гипертриглицеридемии, гиперхолестеринемии, гиперлипидемии, диабета и диабета по типу II.
EA200970398A 2006-10-24 2007-10-22 Производные пиперидин- или пиперазинзамещенной тетрагидронафталин 1-карбоновой кислоты, ингибирующие мтр EA016311B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122817 2006-10-24
PCT/EP2007/061286 WO2008049806A1 (en) 2006-10-24 2007-10-22 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds

Publications (2)

Publication Number Publication Date
EA200970398A1 true EA200970398A1 (ru) 2009-08-28
EA016311B1 EA016311B1 (ru) 2012-04-30

Family

ID=37885794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970398A EA016311B1 (ru) 2006-10-24 2007-10-22 Производные пиперидин- или пиперазинзамещенной тетрагидронафталин 1-карбоновой кислоты, ингибирующие мтр

Country Status (28)

Country Link
US (1) US8114880B2 (ru)
EP (1) EP2076494B1 (ru)
JP (1) JP5506085B2 (ru)
KR (1) KR101415536B1 (ru)
CN (1) CN101528695B (ru)
AR (1) AR063517A1 (ru)
AT (1) ATE475648T1 (ru)
AU (1) AU2007310925B2 (ru)
BR (1) BRPI0717357A2 (ru)
CA (1) CA2664141C (ru)
CL (1) CL2007003042A1 (ru)
CY (1) CY1111010T1 (ru)
DE (1) DE602007008124D1 (ru)
DK (1) DK2076494T3 (ru)
EA (1) EA016311B1 (ru)
HK (1) HK1136823A1 (ru)
IL (1) IL198332A (ru)
JO (1) JO2653B1 (ru)
MX (1) MX2009004386A (ru)
NO (1) NO20092005L (ru)
NZ (1) NZ575615A (ru)
PL (1) PL2076494T3 (ru)
PT (1) PT2076494E (ru)
SI (1) SI2076494T1 (ru)
TW (1) TWI396688B (ru)
UA (1) UA99109C2 (ru)
WO (1) WO2008049806A1 (ru)
ZA (1) ZA200902822B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
ATE469122T1 (de) 2006-10-24 2010-06-15 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
SI2629776T1 (sl) 2010-10-18 2017-12-29 Cerenis Therapeutics Holding Sa Spojine, sestavki in postopki, uporabni za mobilizacijo holesterola
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
JP6960532B2 (ja) * 2018-05-15 2021-11-05 旭化成株式会社 アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2024006701A1 (en) * 2022-06-28 2024-01-04 Stepan Company Method for making dialkyl amino acid ester sulfonates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
BR9714364A (pt) 1996-11-27 2000-03-21 Pfizer Amidas inibidoras da secreção de apo b/mtp
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
DE19963235A1 (de) * 1999-12-27 2001-07-05 Boehringer Ingelheim Pharma Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
ATE469122T1 (de) 2006-10-24 2010-06-15 Janssen Pharmaceutica Nv Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate

Also Published As

Publication number Publication date
AU2007310925A1 (en) 2008-05-02
JP2010507615A (ja) 2010-03-11
SI2076494T1 (sl) 2010-11-30
US8114880B2 (en) 2012-02-14
DK2076494T3 (da) 2010-11-08
CA2664141C (en) 2015-04-28
ATE475648T1 (de) 2010-08-15
NZ575615A (en) 2011-01-28
MX2009004386A (es) 2009-05-08
CA2664141A1 (en) 2008-05-02
PT2076494E (pt) 2010-10-18
US20090325980A1 (en) 2009-12-31
NO20092005L (no) 2009-06-04
CY1111010T1 (el) 2015-06-11
KR101415536B1 (ko) 2014-07-16
JP5506085B2 (ja) 2014-05-28
AR063517A1 (es) 2009-01-28
IL198332A0 (en) 2010-02-17
IL198332A (en) 2012-08-30
CN101528695B (zh) 2013-07-17
AU2007310925B2 (en) 2012-07-26
HK1136823A1 (en) 2010-07-09
EP2076494B1 (en) 2010-07-28
TW200833680A (en) 2008-08-16
TWI396688B (zh) 2013-05-21
BRPI0717357A2 (pt) 2013-10-22
UA99109C2 (ru) 2012-07-25
CN101528695A (zh) 2009-09-09
DE602007008124D1 (de) 2010-09-09
CL2007003042A1 (es) 2008-05-02
KR20090075832A (ko) 2009-07-09
WO2008049806A1 (en) 2008-05-02
ZA200902822B (en) 2010-07-28
JO2653B1 (en) 2012-06-17
PL2076494T3 (pl) 2011-01-31
EP2076494A1 (en) 2009-07-08
EA016311B1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
EA200601660A1 (ru) Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами
BRPI0613754B8 (pt) compostos, éster de um composto, composições farmacêuticas que compreendem o composto, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por análogos de hormônio de tireóide e utilização dos compostos
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200900343A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA200870489A1 (ru) Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы
EA200601120A1 (ru) N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в
BRPI0717314A2 (pt) Derivados de ácido tetra-hidro-naftaleno-1-carboxílico inibidores de mtp
EA200801137A1 (ru) Соединения для ингибирования апоптоза
NO20064601L (no) Mtp-hemmende aryl-piperidiner eller -piperaziner substituert med 5-leddede heterocykler
ATE543508T1 (de) Therapeutische verwendung von gba2
DE60305727D1 (de) Hypoestoxide, derivate und agonisten davon zur verwendung bei der behandlung und prophylaxe von hyperlipidämie

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU